Lab Manager: Virotherapy GMP Site Expands to Enhance Flexibility

News
Published: 14 October 2021 Author: Stefan Beyer, Ph.D., President and Managing Director

Stefan Beyer, PhD, President and Managing Director recently sat down with Lab Manager to discuss ongoing expansion of Vibalogics’ Cuxhaven, Germany facility supporting our CDMO offering for oncolytic viruses, viral vector gene therapy and vaccine products.

To read the Lab Manager article: https://www.labmanager.com/lab-design-and-furnishings/virotherapy-gmp-site-expands-to-enhance-flexibility-26881

We’re the ideal CDMO for your Virotherapy project

Get in touch

SERVICE OFFERING

Looking for something different?

Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.

Related

What to read next

Vibalogics Establishes Scientific Advisory…

Vibalogics, a global contract development and manufacturing organization (CDMO) and recognized leader …

Vibalogics Invests an Additional $50 Milli…

Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced t…

Vibalogics Increases Capacity with additio…

GERMANY-based contract development and manufacturing organization (CDMO) Vibalogics has increased its …